[1]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269-271.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
　HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):269-271.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
点击复制

131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第5期
页码:
269-271
栏目:
论著
出版日期:
2013-09-25

文章信息/Info

Title:
Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation
作者:
侯莎莎;  沈婕;  秦岚
300192 天津, 天津市第一中心医院核医学科
Author(s):
HOU Sha-sha;  SHEN Jie;  QIN Lan
Department of Nuclear Medicine, Tianjin First Center Hospital, Tianjin 300192, China
关键词:
甲状腺肿瘤; 甲状腺球蛋白; 碘放射性同位素
Keywords:
Thyroid neoplasms; Thyroglobulin; Iodine radioisotopes
DOI:
10.3760/cma.j.issn.1673-4114.2013.05.004
摘要:
目的 评价131I全身显像联合血清甲状腺球蛋白(Tg)测定在分化型甲状腺癌(DTC)131I治疗随访中的临床应用价值。方法 153例经手术病理确诊为DTC的患者,均在术后接受了1次以上的131I治疗,每次剂量为1.85~9.25 GBq,131I治疗前测定血清Tg,治疗5d后进行131I全身显像。结果 153例行131I治疗的DTC患者共行血清Tg和131I全身显像检查各为262次,其中55.6%(85/153)的患者的血清Tg水平与131I全身显像均异常,13.7%(21/153)的患者两者均为正常,30.7%(47/153)的患者两者结果不一致,不一致的47例患者经其他影像学检查证实19例131I全身显像异常的患者中有13例异常,28例血清Tg异常的患者中有25例异常.血清Tg诊断DTC转移的灵敏度和特异度分别为89%(110/123)和90% (27/30),而131I全身显像的灵敏度和特异度分别为79.6%(98/123)和80%(24/30)。结论 DTC手术及131I治疗后,常规进行血清Tg测定和131I全身显像检查,对术后判定复发转移灶及制定最佳131I诊疗计划、评价131I疗效具有重要的临床应用价值。
Abstract:
Objective To evaluate the clinical value of 131I whole body scans with that of serum thyroglobulin (Tg)determination for the follow-up of differentiated thyroid carcinoma(DTC)receiving postoperative 131I therapy.Methods There were 153 patients with differentiated thyroid cancer receiving postoperative 131I therapy for more than one time at the dose of 1.85-9.25 GBq.Serum Tg levels were measured before 131I treatment and 131I whole body scans were performed 5 days after treatment.Results Among the 153 patients who underwent 131I therapy, serum Tg levels and 131I-whole body scans were both abnormal in 85 patients (55.6%).Both examinations were negative in 21 patients (13.7%).In the 19 patients with abnormal 131I whole body scans only, image study with means of 18F-FDG, SPECT, CT, ultrasonic or whole body bone scan revealed lesions in 13 patients; while in the 28 patients with abnormal Tg levels only, image study with the above means revealed lesions in 25 patients.The sensitivity of Tg positiveness and 131I whole body scans positiveness were 89% (110/123) and 79.6% (98/123) respectively, and the specificity were 90% (27/30)and 80% (24/30)respectively.Conclusions Routine serum Tg measurement and 131I whole body scans in patients with DTC with 131I radiotherapy after thyroidectomy is essential.It is of greatly clinical value in early detecting metastases, optimizing the 131I treatment protocol and evaluating the curative effect.

参考文献/References:

[1] Kucukalc 6-Selimovc E, Alagic J,Valjevac A, et al. The value of serum thyreoglobulin levels and whole body(l-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy.Coll Antropol, 2012,36 suppl 2:S67-71.
[2] Lind P. 131I whole body scintigraphy in thyroid cancer patients. Q J NucI Med, 1999, 43(3):188-194.
[3] Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med, 1998,39(9):1531-1536.
[4] Zanotti-Fregonara P, Keller I,Rubello D, et al. Thyrotropin varia-tions may explain some positive radioiodine therapy scans in patients with negative diagnostic scans. J Endocrinol Invest, 2009,32(3):267-271.
[5] Alagic-Smailbegovic J, Kucukalic-Selimovic E,Setic I,et al. Impor-tance of measurement of thyroglobulin and anti-thyroglobulin anti-bodies in differentiated thyroid cancer. Coll Antropol, 2012, 36suppl 2:S33-38.
[6] Fatourechi V, Hay ID. Treating the patient with differentiated thy-roid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases:including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med,2000,30(2):107-114.
[7] Dong MJ, Liu ZF, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan:a meta-analysis. Nucl Med Commum, 2009, 30(8):639-650.
[8] Kunawudhi A, Pak-art R, Keelawat S, et al. Detection of subcen-timeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiatedthyroid carcinoma and high serumthyroglobulin but negative 131I whole-body scan. Clin Nucl Med,2012, 37(6):561-567.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[9]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[10]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[11]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[12]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[13]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
　LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[14]邱忠领,罗全勇.甲状腺球蛋白与分化型甲状腺癌[J].国际放射医学核医学杂志,2009,33(2):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
　QIU Zhong-ling,LUO Quan-yong.Thyroglobulin and differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
[15]林军,缪蔚冰,吴立坚,等.131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义[J].国际放射医学核医学杂志,2006,30(3):161.
　LIN Jun,MIAO Wei-bing,WU Li-jian,et al.The value of thyroglobulin measured and 131I-whole body scan on the differentiated thyroid carcinoma with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):161.

备注/Memo

备注/Memo:
收稿日期:2012-10-23。
基金项目:天津市卫生局科技基金(11KG131)
通讯作者:沈婕,Email:shenjie_vip@126.com
更新日期/Last Update: 1900-01-01